Rational approach in the management of Pseudomonas aeruginosa infections.

PURPOSE OF REVIEW

This review details the management of Pseudomonas aeruginosa infections covering both current and future treatment options that are and may be available for the clinicians.

RECENT FINDINGS

Pseudomonas aeruginosa infections are a great concern in hospital-acquired infections with very limited therapeutic options. The increasing antibiotic resistance has led to a need for different treatment choices that range from the use of new antibiotics to new nonantibiotic alternative agents to kill or disarm the pathogen.

SUMMARY

New molecules such as ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam have shown an adequate activity against P. aeruginosa, especially against multidrug resistance strains. Other nonantibiotic alternative treatments, such as antibodies, bacteriocins or phage therapy, have shown promising results, but future clinical studies are needed.